Spinocerebellar Ataxia Type 31 Exacerbated by Anti-amino Terminal of Alpha-enolase Autoantibodies.

Abstract

We herein report a 61-year-old woman who was genetically diagnosed with spinocerebellar ataxia type 31 whose symptoms were modified by anti-amino terminal of alpha-enolase (NAE) antibodies, known as a biomarker of Hashimoto's encephalopathy (HE), and ultimately responded to immunotherapy. The relative titers of anti-NAE antibodies increased when her cerebellar ataxia showed acute deterioration and decreased after immunotherapy. This is the first report of cerebellar ataxia associated with genetic spinocerebellar ataxia with concomitant cerebellar type HE. Physicians should be mindful of measuring anti-NAE antibodies to prevent overlooking patients with genetic spinocerebellar ataxia with treatable simultaneous ataxic diseases.

• Authors: Satoshi Zeniya, Nobuo Sanjo, Hiroya Kuwahara, Kinya Ishikawa, Miwa Higashi, Akiko Matsunaga, Makoto Yoneda, Hidehiro Mizusawa, Takanori Yokota
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 61 Issue 18 Pg. 2793-2796 ( 2022) ISSN: 1349-7235 [Electronic] Japan
• PMID: 36104177 (Publication Type: Case Reports, Journal Article)

Chemical References

• Autoantibodies
• Phosphopyruvate Hydratase

Topics

• Autoantibodies
• Cerebellar Ataxia (diagnosis)
• Encephalitis
• Female
• Hashimoto Disease
• Humans
• Middle Aged
• Phosphopyruvate Hydratase
• Spinocerebellar Ataxias